Quantitative Magnetization Transfer MRI for Evaluation of Renal Fibrosis

Overview

About this study

The purpose of this study is to evaluate whether or not an MRI technique (quantitiative magnetization transfer or qMT) in narrowing human kidneys is feasible, reproducible, and predicts recovery.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Between ages 40 and 80 years old.

- Patients with hypertension (BP>140/90 mmHg) and/or requirement for two or more
antihypertensive medications for more than 4 weeks.

- Serum creatinine under 2.2 and 2.0 mg/dL for men and women, respectively (Caucasians).
Values for African-American subjects are slightly higher (2.4 mg/dL, males; 2.1 mg/dL
females).

- No contraindications to angiography: severe contrast allergy.

- No contraindications to no-contrast MR evaluations: e.g. pacemaker or magnetically
active metal fragments, claustrophobia.

- Patients have the ability to comply with protocol

- Patients are competent and able to provide written informed consent

Exclusion Criteria:

- Patient has serum creatinine >2.2 mg/dL for men and >2.0 mg/dL for women (Caucasians);
>2.4 mg/dL for men and >2.1 mg/dL for women (African American).

- RVD in a solitary kidney

- Patients have clinically significant medical conditions within the prior six months:
e.g. myocardial infarction, congestive heart failure, stroke, that would, in the
opinion of the investigators, compromise the safety of the patient.

- Uncontrolled hypertension (Systolic BP >180 mmHg despite therapy).

- Diabetes requiring insulin or oral hypoglycemic medications.

- Evidence of hepatitis B or C, or HIV infection.

- Requirement for potentially nephrotoxic drugs; e.g., non-steroidal anti-inflammatory
drugs.

- Cardiac ejection fraction less than 30%.

- History of deep venous thrombosis within 3 months of enrollment.

- Kidney transplant.

- Pacemaker, implantable defibrillator or other contraindication to MRI

- Inability to comply with breath-hold for 20 seconds

- Any active malignancy and undergoing therapy

- Patients are pregnant.

- Kidney or ureteric stone

- Another known acute or chronic kidney disease

- Federal medical center inmates.

- Latex allergy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/28/22. Questions regarding updates should be directed to the study team contact

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lilach Lerman, M.D., Ph.D.

Open for enrollment

Contact information:

Beverly Tietje C.S.T.

(507) 255-0401

Tietje.Beverly@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20507606

Mayo Clinic Footer